Next Article in Journal
Viral Metagenomics on Blood-Feeding Arthropods as a Tool for Human Disease Surveillance
Next Article in Special Issue
iTRAQ-Based Quantitative Proteomic Analysis of the Potentiated and Dormant Antler Stem Cells
Previous Article in Journal
α6β4 Integrin Genetic Variations (A380T and R1281W) and Breast Cancer Risk in an Argentinian Population
Previous Article in Special Issue
Drought-Responsive Mechanisms in Plant Leaves Revealed by Proteomics
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(10), 1744; doi:10.3390/ijms17101744

A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors

1
Multiple Sclerosis Department, Florey Institute of Neuroscience and Mental Health, Melbourne, VIC 3052, Australia
2
Center for Cancer and Immunology Research, Children’s National Medical Center, Washington, DC 20010, USA
*
Author to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Received: 1 July 2016 / Revised: 23 September 2016 / Accepted: 10 October 2016 / Published: 19 October 2016
(This article belongs to the Collection Advances in Proteomic Research)
View Full-Text   |   Download PDF [1883 KB, uploaded 19 October 2016]   |  

Abstract

Brain tumors are the leading cause of cancer-related deaths in children, and medulloblastoma is the most prevalent malignant childhood/pediatric brain tumor. Providing effective treatment for these cancers, with minimal damage to the still-developing brain, remains one of the greatest challenges faced by clinicians. Understanding the diverse events driving tumor formation, maintenance, progression, and recurrence is necessary for identifying novel targeted therapeutics and improving survival of patients with this disease. Genomic copy number alteration data, together with clinical studies, identifies c-MYC amplification as an important risk factor associated with the most aggressive forms of medulloblastoma with marked metastatic potential. Yet despite this, very little is known regarding the impact of such genomic abnormalities upon the functional biology of the tumor cell. We discuss here how recent advances in quantitative proteomic techniques are now providing new insights into the functional biology of these aggressive tumors, as illustrated by the use of proteomics to bridge the gap between the genotype and phenotype in the case of c-MYC-amplified/associated medulloblastoma. These integrated proteogenomic approaches now provide a new platform for understanding cancer biology by providing a functional context to frame genomic abnormalities. View Full-Text
Keywords: medulloblastoma; MYC; quantitative proteomics medulloblastoma; MYC; quantitative proteomics
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Staal, J.A.; Pei, Y.; Rood, B.R. A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors. Int. J. Mol. Sci. 2016, 17, 1744.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top